Galmed Pharma

GLMD NASDAQ
6.77
+0.07
+0.99%
Opening 09:36 05/23 EDT
Open
6.62
Prev Close
6.70
High
6.77
Low
6.37
Volume
5.49K
Avg Vol (3M)
111.14K
52 Week High
27.06
52 Week Low
5.58
% Turnover
0.03%
Market Cap
142.85M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company's Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.
MORE >

Recently

Name
Price
%Change